US30161Q1040 - Common Stock
NASDAQ:EXEL (2/2/2023, 8:50:10 AM)-0.05 (-0.31%)
GICS Sector | Health Care | ||
GICS Industry | Biotechnology |
Valuation | Growth | ||
Profitability | Health | ||
Dividend |
Earnings (Last) | 11-01 2022-11-01/amc | Earnings (Next) | 02-15 2023-02-15 |
Ins Owners | 1.59% | Inst Owners | 85.45% |
Market Cap | 5.65B | Shares | 322.56M |
PE | 18.43 | Fwd PE | 17.57 |
Dividend Yield | N/A | Analysts | 81.82 |
IPO | 04-11 2000-04-11 |
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. The company is headquartered in Alameda, California and currently employs 954 full-time employees. The company went IPO on 2000-04-11. The firm is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
EXELIXIS INC
1851 Harbor Bay Parkway
Alameda CALIFORNIA 94502
P: 16508377000.0
CEO: Michael M. Morrissey
Employees: 954
Website: https://www.exelixis.com/
Exelixis (EXEL) had a mixed ruling in its Cabometyx patent trial versus MSN Laboratories
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.
Here you can normally see the latest stock twits on EXEL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: